Welcome to CYTAVIS BioPharma GmbH

CYTAVIS BiopPharma GmbH, based in Hamburg/Germany, is a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological diseases. The company’s portfolio comprises pre-clinical and clinical programs.

Latest News

CYTAVIS’ Aviscumine Improves Survival of Patients with Metastatic Melanoma in a Phase II Trial

Hamburg/Germany, July 13, 2011 – CYTAVIS BioPharma GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced Phase II data demonstrating that its lead compound Aviscumine (CY-503), an immune potentiator, may improve survival of patients with refractory metastatic melanoma (stage IV).

CYTAVIS STARTS RECRUITING PATIENTS FOR PHASE II CLINICAL TRIAL WITH AVISCUMINE (CY-503) IN METASTATIC COLORECTAL CARCINOMA PATIENTS IN AUSTRIA

Hamburg/Germany, March 15, 2011 – CYTAVIS BioPharma today announced the start of patient recruitment for a Phase II trial of its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma in Austria.

CYTAVIS EXPANDS PHASE II CLINICAL TRIAL WITH AVISCUMINE (CY-503) IN METASTATIC COLORECTAL CARCINOMA PATIENTS

Hamburg/Germany, August 25, 2010 – CYTAVIS BioPharma currently is conducting a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma. Already, more than 20 German study centers are participating in the trial.